Why the study?
Does single subcutaneous administration of ACT-246475 achieve adequate inhibition of platelet aggregation and safety in healthy male subjects?
Does single subcutaneous administration of ACT-246475 achieve adequate inhibition of platelet aggregation and safety in healthy male subjects?
Single subcutaneous administration of ACT-246475 provides rapid and sustained inhibition of platelet aggregation, supporting further investigation for coronary artery disease.
Answers are grounded in this paper and cite their sources.
Supports CAD trial development; extends healthy-subject RCT data on subcutaneous platelet inhibition.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Juif et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: